AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00494741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine
Description: Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight > 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
Study NCT00876265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero
Description: Belotero, injectable hyaluronic acid gel device, implanted into the nasolabial fold in the Treatment Phase of the study (multiple injections of 0.1 to 0.2 mL, up to a maximum of 3 mL over 2 treatment sessions). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered.
Study NCT00876265 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zyplast
Description: Zyplast Collagen Implant, an injectable dermal collagen device, implanted into the nasolabial fold in the Treatment Phase of the study (average injection of 1.0 mL). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered. Zyplast was obtained by each site from commercially available supplies.
Study NCT02134275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole body vibration training
Description: Each whole body vibration session will consist of a 20 min timed stand on the vibration platform where participants will stand with their knees in a slightly flexed position (120°) while the plate oscillates. The vibration frequency will be set at ranges between 20-40Hz and the amplitude set at 2mm displacement.
Study NCT02134275 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Participants in this group will be asked to not make any significant changes to their lifestyle behaviors, such as diet and exercise, for the duration of the study.
Study NCT05040737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS membrane versus PMMA membrane,
Description: Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.
Study NCT00616993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate
Description: Difluprednate
Study NCT00616993 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study NCT01173536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449
Description: Oral repeating dose
Study NCT00495131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a plus ribavirin
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 48 weeks
Study NCT01041729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
Study NCT01041729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment.
Study NCT02034422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Antioxidant
Description: Consisting of vitamins C, E and alpha lipoic acid.
Study NCT02034422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation
Description: 8 weeks of exercise rehabilitation
Study NCT02847468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG Positron Emission Tomography
Description: Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FDG) before treatment with Sorafenib is started and 1 month after treatment started.
Study NCT02847468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FCH Positron Emission Tomography
Description: Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FCH) before treatment with Sorafenib is started and 1 month after treatment started.
Study NCT02761291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administrated 600\~1250 mg/m\^2 intravenously according to the body surface area at day 1 and day 8 in a 28 day-treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times. The first dose level of gemcitabine will be started at 800 mg/m\^2. If no subject suffered the dose limit toxicity, 1000 mg/m\^2 and even 1250 mg/m\^2 will be started by order. If subjects suffered the dose limit toxicity in 800 mg/m\^2, the 600 mg/m\^2 will be started.
Study NCT02761291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: Valproic acid will be administrated orally by the fixed dose 12.5 mg/kg/day according to instructions from day 1 to day 14 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
Study NCT02761291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir will be administrated orally by the fixed dose 1350 mg/day (creatinine clearance rate ≥ 60 mL/min) or 900 mg/day (creatinine clearance rate ≥ 40 mL/min and \< 60 mL/min) from day 9 to day 15 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
Study NCT03660631 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CVRS Intervention
Description: 1. Evaluate gaps in therapy~2. Contact patients regularly by email, phone and/or text message~3. Assess and counsel for medication adherence, side effects, life-style behaviors~4. Develop an action plan and send recommendations to provider
Study NCT03660631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CVRS Intervention
Description: 1. Evaluate gaps in therapy~2. Contact patients regularly by email, phone and/or text message~3. Assess and counsel for medication adherence, side effects, life-style behaviors~4. Develop an action plan and send recommendations to provider
Study NCT00364130 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low magnitude mechanical stimulus
Description: 10 minute daily treatment sessions standing on the low magnitude mechanical stimulus device
Study NCT00364130 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (inactive) low magnitude mechanical stimulus
Description: 10 minute daily treatments standing on a placebo version of a low magnitude mechanical stimulus device
Study NCT00813033 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: patient decision aid for endoscopy
Description: patient decision aid will be administered at the point of decision making
Study NCT03385161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Study NCT03385161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Study NCT00440778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: 100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion
Study NCT00440778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: 100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion
Study NCT01482351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPAP adherence intervention
Description: Critical factors were (1) OSA education, treatment expectations, and ways to minimize barriers and facilitate CPAP use; (2) promotion of a positive initial CPAP experience; (3) motivational interviewing to reinforce participants' health-related goals and CPAP self-efficacy; (4) anticipatory guidance and follow-up of common CPAP problems; and (5) social support by a study partner. Trained project staff provided the intervention by phone and face to face for a total of 12-14 hours over the 1 year project.
Study NCT01482351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention control intervention
Description: This intervention, provided by phone and face to face by project staff, provided equal time and attention. Critical factors were (1) education about OSA and risks, (2) education about memory, and other health topics of interest to the participants; (3) motivational interviewing to reinforce participants' health-related goals; (4) building rapport, and (5) social support by a study partner.
Study NCT00055471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054 10 mg
Description: 1 x 10 mg oral tablets once daily
Study NCT00055471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054 15 mg
Description: 1 x 10 mg + 2 x 2.5 mg oral tablets once daily
Study NCT00055471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054 22.5 mg
Description: 2 x 10 mg + 2 x 2.5 mg oral tablets once daily
Study NCT00295971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study NCT00295971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Study NCT00295971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00295971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Study NCT00295971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Study NCT00295971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT00295971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated peripheral blood stem cell transplantation
Study NCT00295971 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Study NCT04623385 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone
Description: 1. The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days~2. The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days
Study NCT04623385 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: The standard therapy
Description: infected patients will receive the standard therapy for COVID-19 for 14 days
Study NCT05425589 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Adjustable strabismus surgery
Description: Our objective was to assess the long-term success of adjustable suture strabismus surgery in terms of postoperative alignment and complications.
Study NCT03131453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP520 50mg
Description: 50 mg capsule
Study NCT03131453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP520 15mg
Description: 15 mg capsule
Study NCT03131453 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo for 15 and 50 mg capsules
Study NCT01278160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.
Study NCT01278160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.
Study NCT01278160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
Study NCT03442283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin mineral supplementation
Description: supplementation with a vitamin or mineral: vitamin A, β-carotene, B1, B2, B3 (niacin), B6, B10 (folic acid), C, D and E, calcium, iron, zinc, magnesium and selenium. Also, multivitamins, antioxidants, B-complex and the combination of calcium and vitamin D.
Study NCT04041739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fungal osteomyelitis culture and sensitivity
Description: swabs from ulcer tissue and bone biopsy for culture and sensitivity test and blood sampling
Study NCT04570267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL324
Description: Sterile solution of recombinant anti G-CSF receptor monoclonal antibody for injection
Study NCT04570267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution of CSL324 formulation buffer for injection
Study NCT02149615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retinal nerve fibre layer measurement
Description: Measurement of retinal nerve fibre layer thickness using optic coherence tomography.
Study NCT02149615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retinal nerve fibre layer measurement
Description: Measurement of retinal nerve fibre layer thickness using optic coherence tomography.
Study NCT03098628 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV Vaccine
Description: PCV vaccination
Study NCT03098628 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV Vaccine
Description: PCV vaccination
Study NCT03091660 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG Solution
Description: Given intravesically
Study NCT03091660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Tokyo-172 Strain Solution
Description: Given intravesically
Study NCT03091660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Tokyo-172 Strain Vaccine
Description: Given ID
Study NCT03091660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03091660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01173536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: Oral single dose
Study NCT04120337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RemovAid device + lidocaine patch
Description: The RemovAid device incises the skin and grasps the implant for removal. A lidocaine patch will be used prior to incision.
Study NCT04120337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique + lidocaine injection
Description: Using scalpel, tweezers, and forceps to remove a subdermal implant. A lidocaine injection will be used prior to incision.
Study NCT04120337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RemovAid device + lidocaine injection
Description: The RemovAid device incises the skin and grasps the implant for removal. A lidocaine injection will be used prior to incision.
Study NCT03829683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5% in water
Description: 50mL intravenously every 6 hours
Study NCT03829683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5% in water
Description: 50mL intravenously every 6 hours
Study NCT00606099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbivudine
Description: To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.
Study NCT01173536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Oral repeating dose
Study NCT00606099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adefovir dipivoxil
Description: Active Comparator
Study NCT01248468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin, acetaminophen and caffeine
Description: 2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
Study NCT01248468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: 100 mg Sumatriptan
Study NCT01248468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04275869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle
Description: A 3-month internet-based program focusing on the promotion of healthy lifestyles. The treatment protocol comprises 9 modules which incorporate psychological strategies to promote healthy lifestyles by gradually changing eating and physical activity habits.
Study NCT03008343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irreversible Electroporation
Description: One kind of electric ablation machine from Angiodynamic company (USA)
Study NCT04546243 — intervention group
Intervention type: PROCEDURE
Intervention: resection group
Description: patients received VATS
Study NCT04546243 — intervention group
Intervention type: RADIATION
Intervention: radiotherapy group
Description: patients received radiotherapy
Study NCT01992081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated telehealth system
Description: The automated telehealth system (used within its intended use) comprises of CE marked medical devices and a CE marked step counter (Fitbug®), all being used within their intended use. Coaching by investigators is performed during the study visits and is aimed to enhance physical activity in patients across a spectrum of COPD severity, in addition to the usual care.
Study NCT01992081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants will receive usual care associated with Chronic Obstructive Pulmonary Disease (COPD)
Study NCT01992081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants will receive usual care associated with Chronic Obstructive Pulmonary Disease (COPD)
Study NCT03801109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric group
Description: Participants in this group performed 5 sessions per week for 8 weeks (40 sessions in total) . The time of each session is 90 minutes and the chamber pressure is 1.4 ATA with a 100% oxygen mask.
Study NCT03801109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic group
Description: There will be 5 sessions per week for 2 consecutive weeks (10 sessions in total), stimulating the left motor cortex at high frequencies, 10 Hz, for 30 minutes.
Study NCT03801109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical group
Description: A protocol of low-impact physical exercise will be performed twice a week for 8 weeks, with a total of 16 sessions.
Study NCT03801109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline group
Description: This group will be the control group that did not take any action, perform the activities of daily life
Study NCT03419624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10 mg tablet once daily
Study NCT03419624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg [Bydureon]
Description: Exenatide 2 mg injection once weekly
Study NCT03419624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide 2 mg [Bydureon]
Description: Exenatide 2 mg injection once weekly
Study NCT03419624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral tablet once daily
Study NCT03419624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral tablet once daily
Study NCT03419624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo injection once weekly
Study NCT03008343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation
Description: One kind of electric ablation machine from Angiodynamic company (USA)
Study NCT03008343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer
Description: Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
Study NCT00616161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: 0.5 microgram/kg/min IV for 6 hours
Study NCT00616161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: 1.0 microgram/kg/min IV for 6 hours
Study NCT00616161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: 1.5 microgram/kg/min IV for 6 hours
Study NCT00616161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00445692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Given Orally (PO)
Study NCT00445692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT00445692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given Orally (PO)